Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-26 @ 11:13 PM
Ignite Modification Date: 2025-12-26 @ 11:13 PM
NCT ID: NCT05179512
Eligibility Criteria: Inclusion Criteria: * Age between 40-80 years \[0,0\] days * Diagnosis of COPD \[all available data, 0\] days * Clinical history of at least 1 COPD exacerbation \[all available data, -43\] days Exclusion Criteria: * COPD exacerbation \[-42, 0\] days * Asthma, eczema, atopic dermatitis, allergic rhinitis \[-180, 0\] days * Known respiratory disorder other than COPD e.g. pulmonary fibrosis or interstitial lung disease (ILD), sarcoidosis, lymphangioleiomyomatosis, primary/pulmonary tuberculosis, cystic fibrosis, pulmonary hypertension/other pulmonary heart disease, lung/pulmonary malignancies, alpha-1 antitrypsin deficiency, pneumoconioses and other lung diseases due to external agents \[all available data, 0\] days * Narrow angle glaucoma or prostatic hyperplasia or obstruction of the neck of the bladder \[-180, 0\] days * At least one 30-day supply prescription claims for oral alfuzosin, doxazosin, tamsulosin, silodosin, finasteride 5 mg, dutasteride \[-180,0\] days * Lung transplant or lung volume reduction surgery (LVRS) \[all available data, 0\] days * Daily long term oxygen therapy (LTOT) \[all available data, 0\] days * Beta-blockers (except eye drops) \[-180, 0\] days * Evidence of alcohol, drug or solvent abuse \[-180, 0\] days * Use of salmeterol, tiotropium and fluticasone containing inhaler use \[-180, 0\] days
Healthy Volunteers: False
Sex: ALL
Minimum Age: 40 Years
Maximum Age: 80 Years
Study: NCT05179512
Study Brief:
Protocol Section: NCT05179512